Collaborative calibration of 10% allelic frequencies of mutation samples
| No. | Mutation | BGI | CapitalBio | Annoroad | Geneplus | Geneplus | BerrYgenomics | Ave |
| BGIseq 500 | Proton | Nextseq550 | Nextseq 500 | MGI 2000 | Nextseq 500 | |||
| 1 | Wild type | / | / | / | / | / | / | |
| 2 | KRAS:p.G12D | 8.57% | 9.56% | 5.19% | 6.6% | 7.0% | 9.9% | 7.81% |
| 3 | KRAS:p.G12C | 13.76% | 11.50% | 8.66% | 10.6% | 9.3% | 12.4% | 11.04% |
| 4 | KRAS:p.G12A | 12.56% | 9.89% | 6.95% | 10.0% | 9.4% | 11.6% | 10.07% |
| 5 | KRAS:p.G13D | 8.01% | 8.37% | 6.19% | 6.9% | 5.4% | 6.3% | 6.87% |
| 6 | KRAS:p.G12S | 10.97% | 10.17% | 8.03% | 7.9% | 8.8% | 7.9% | 8.97% |
| 7 | KRAS:p.G13C | 10.42% | 7.49% | 5.28% | 8.6% | 8.3% | 8.5% | 8.09% |
| 8 | NRAS:p.Q61K | 11.97% | 12.80% | 8.97% | 7.7% | 7.9% | 8.8% | 9.68% |
| 9 | NRAS:p.Q61R | 10.76% | 13.55% | 11.06% | 9.6% | 10.1% | 9.9% | 10.81% |
| 10 | BRAF:p.G469A | 9.21% | 9.87% | 4.73% | 8.9% | 5.2% | 7.3% | 7.55% |
| 11 | BRAF:p.L597V | 8.51% | 13.48% | 6.47% | 6.3% | 6.8% | 9.4% | 8.49% |
| 12 | PIK3CA:p.E542K | 10.38% | / | 7.33% | 7.7% | 7.8% | 8.7% | 8.40% |
| 13 | PIK3CA:p.E545K | 11.34% | 8.89% | 5.08% | 7.9% | 7.7% | 8.8% | 8.30% |
| 14 | PIK3CA:p.H104R | 9.09% | 9.28% | 6.46% | 5.7% | 6.1% | 6.1% | 7.13% |
| 15 | PIK3CA:p.H1047L | 8.49% | 8.83% | 4.64% | 6.6% | 6.7% | 5.1% | 6.72% |
| 16 | EGFR:p.T790M | 13.13% | 10.81% | 7.29% | 7.3% | 6.1% | 6.7% | 8.56% |
| 17 | EGFR:p.G719S | 10.53% | 12.49% | 7.79% | 7.8% | 8.5% | 9.8% | 9.47% |
| 18 | EGFR:p.L858R | 14.12% | 10.97% | 11.19% | 12.1% | 13.2% | 16.2% | 12.96% |
| 19 | EGFR:p.E746_A750del | 8.11% | 7.80% | 8.84% | 6.7% | 6.0% | 14.3% | 8.63% |
| 20 | EGFR:p.p.L747_E749del | 8.85% | 8.40% | 7.20% | 6.6% | 6.6% | 12.0% | 8.27% |
| 21 | EGFR:p.E746_S752>I | 12.81% | / | 8.28% | 4.3% | 5.1% | 11.6% | 8.42% |
| 22 | MET gain | 7.78 | / | 4.52 | 3.9 | / | / | 5.40 |
| 23 | EGFR gain | 9.77 | / | 6.14 | 4.7 | / | / | 6.87 |
BRAF, B-type Raf kinase; EGFR, epidermal growth factor receptor; KRAS, kirsten rat sarcoma viral oncogene; MET, mesenchymal-epithelial transition factor; NRAS, neuroblastoma ras oncogene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.